share_log

君聖泰醫藥-B：2023環境、社會及管治報告

HIGHTIDE-B: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Hong Kong Stock Exchange ·  Apr 26 20:06
Summary by Futu AI
君聖泰醫藥-B（股票代碼：2511.HK）發佈了2023年環境、社會及管治報告，展示了公司在綠色經營、社會責任和公司治理方面的成就與承諾。報告中，公司管理層強調了尋求在創新藥物開發與社會責任、環境保護之間的平衡，並致力於實現長期可持續發展。公司在環境保護方面的努力包括優化企業運營管理流程，減少廢棄物產生，積極採用環保材料，並在研發過程中充分考慮環境因素。此外，公司持續優化治理結構，確保企業平穩且合規運營，並建立了內部控制和合規體系。在履行社會責任方面，君聖泰與多個非政府組織合作，開展健康教育活動，提高民眾健康意識。展望未來，公司將持續提升研發創新能力，堅持綠色發展，並與各利益相關方共同推動行業發展與進步。
君聖泰醫藥-B（股票代碼：2511.HK）發佈了2023年環境、社會及管治報告，展示了公司在綠色經營、社會責任和公司治理方面的成就與承諾。報告中，公司管理層強調了尋求在創新藥物開發與社會責任、環境保護之間的平衡，並致力於實現長期可持續發展。公司在環境保護方面的努力包括優化企業運營管理流程，減少廢棄物產生，積極採用環保材料，並在研發過程中充分考慮環境因素。此外，公司持續優化治理結構，確保企業平穩且合規運營，並建立了內部控制和合規體系。在履行社會責任方面，君聖泰與多個非政府組織合作，開展健康教育活動，提高民眾健康意識。展望未來，公司將持續提升研發創新能力，堅持綠色發展，並與各利益相關方共同推動行業發展與進步。
JUN SHENG TAI PHARMACEUTICAL-B (STOCK CODE: 2511.HK) RELEASED ITS 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT SHOWCASING THE COMPANY'S ACHIEVEMENTS AND COMMITMENTS IN GREEN MANAGEMENT, SOCIAL RESPONSIBILITY AND CORPORATE GOVERNANCE. IN THE REPORT, THE COMPANY'S MANAGEMENT EMPHASIZED SEEKING A BALANCE BETWEEN INNOVATIVE DRUG DEVELOPMENT AND SOCIAL RESPONSIBILITY, ENVIRONMENTAL PROTECTION, AND COMMITTED TO LONG-TERM SUSTAINABILITY. The company's efforts to protect the environment include optimizing business operations management processes, reducing waste generation, actively adopting environmentally friendly materials, and taking environmental factors into account during R&D. In addition, the company continuously optimizes its governance structure, ensures smooth and compliant operations, and establishes internal control and compliance systems. In the area of social responsibility, Jun Sengtai cooperates with various NGOs to conduct health education activities and raise public health awareness. Looking ahead, the company will continuously enhance R&D and innovation capabilities, stick to green development, and jointly promote industry development and progress with stakeholders.
JUN SHENG TAI PHARMACEUTICAL-B (STOCK CODE: 2511.HK) RELEASED ITS 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT SHOWCASING THE COMPANY'S ACHIEVEMENTS AND COMMITMENTS IN GREEN MANAGEMENT, SOCIAL RESPONSIBILITY AND CORPORATE GOVERNANCE. IN THE REPORT, THE COMPANY'S MANAGEMENT EMPHASIZED SEEKING A BALANCE BETWEEN INNOVATIVE DRUG DEVELOPMENT AND SOCIAL RESPONSIBILITY, ENVIRONMENTAL PROTECTION, AND COMMITTED TO LONG-TERM SUSTAINABILITY. The company's efforts to protect the environment include optimizing business operations management processes, reducing waste generation, actively adopting environmentally friendly materials, and taking environmental factors into account during R&D. In addition, the company continuously optimizes its governance structure, ensures smooth and compliant operations, and establishes internal control and compliance systems. In the area of social responsibility, Jun Sengtai cooperates with various NGOs to conduct health education activities and raise public health awareness. Looking ahead, the company will continuously enhance R&D and innovation capabilities, stick to green development, and jointly promote industry development and progress with stakeholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.